## Gene L Bowman

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7234057/publications.pdf

Version: 2024-02-01

44 papers 2,562 citations

304743

22

h-index

302126 39 g-index

50 all docs

50 docs citations

50 times ranked

4414 citing authors

#	Article	IF	CITATIONS
1	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.8	310
2	White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 107-117.	3.7	250
3	Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology, 2007, 68, 1809-1814.	1.1	246
4	Uric Acid as a CNS Antioxidant. Journal of Alzheimer's Disease, 2010, 19, 1331-1336.	2.6	197
5	Bloodâ€brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimer's and Dementia, 2018, 14, 1640-1650.	0.8	189
6	Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology, 2012, 78, 241-249.	1.1	186
7	Nutrition for the ageing brain: Towards evidence for an optimal diet. Ageing Research Reviews, 2017, 35, 222-240.	10.9	161
8	Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. Brain, Behavior, and Immunity, 2017, 62, 203-211.	4.1	91
9	Ascorbic Acid and the Brain: Rationale for the Use against Cognitive Decline. Nutrients, 2014, 6, 1752-1781.	4.1	76
10	Ascorbic Acid and Rates of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 93-98.	2.6	75
11	Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimer's Research and Therapy, 2018, 10, 66.	6.2	67
12	Memory, Mood, and Vitamin D in Persons with Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 547-555.	2.8	65
13	Dyslipidemia and Blood-Brain Barrier Integrity in Alzheimer's Disease. Current Gerontology and Geriatrics Research, 2012, 2012, 1-5.	1.6	63
14	Ascorbic acid, cognitive function, and Alzheimer's disease: A current review and future direction. BioFactors, 2012, 38, 114-122.	5.4	52
15	An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 71.	6.2	49
16	One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond. Alzheimer's Research and Therapy, 2017, 9, 43.	6.2	46
17	Reliability and Validity of Food Frequency Questionnaire and Nutrient Biomarkers in Elders With and Without Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2011, 25, 49-57.	1.3	43
18	ICP-MS/MS-Based Ionomics: A Validated Methodology to Investigate the Biological Variability of the Human Ionome. Journal of Proteome Research, 2017, 16, 2080-2090.	3.7	43

#	Article	IF	CITATIONS
19	Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood–Brain Barrier Permeability in Older Adults. Journal of Proteome Research, 2019, 18, 1162-1174.	3.7	40
20	Plasma omega-3 PUFA and white matter mediated executive decline in older adults. Frontiers in Aging Neuroscience, 2013, 5, 92.	3.4	39
21	Alzheimer's disease and the blood–brain barrier: past, present and future. Aging Health, 2008, 4, 47-57.	0.3	38
22	Serum vitamin d concentrations are associated with falling and cognitive function in older adults. Journal of Nutrition, Health and Aging, 2012, 16, 898-901.	3.3	38
23	Associations of Omega-3 fatty acids with brain morphology and volume in cognitively healthy older adults: A narrative review. Ageing Research Reviews, 2021, 67, 101300.	10.9	26
24	Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group. The Lancet Healthy Longevity, 2022, 3, e501-e512.	4.6	26
25	A bloodâ€based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 953-963.	3.7	22
26	Randomized Trial of Marine n-3 Polyunsaturated Fatty Acids for the Prevention of Cerebral Small Vessel Disease and Inflammation in Aging (PUFA Trial): Rationale, Design and Baseline Results. Nutrients, 2019, 11, 735.	4.1	17
27	Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. Journal of Alzheimer's Disease, 2017, 60, 1641-1652.	2.6	16
28	Personalized nutrition for dementia prevention. Alzheimer's and Dementia, 2022, 18, 1424-1437.	0.8	16
29	Cross-sectional associations of total plasma homocysteine with cortical $\hat{l}^2$ -amyloid independently and as a function of omega 3 polyunsaturated fatty acid status in older adults at risk of dementia. Journal of Nutrition, Health and Aging, 2017, 21, 1075-1080.	3.3	14
30	Comparisons of Plasma/Serum Micronutrients Between Okinawan and Oregonian Elders: A Pilot Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2010, 65A, 1060-1067.	3.6	11
31	Biomarkers for early detection of Parkinson disease. Neurology, 2017, 89, 1432-1434.	1.1	11
32	Nutrient Biomarker Patterns, Cognitive Function, and Mri Measures of Brain Aging. Neurology, 2012, 78, 1281-1282.	1.1	7
33	Dietary patterns in early life pay dividends for midlife cognitive performance. Neurology, 2019, 92, 645-646.	1.1	7
34	Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer's Disease. Cells, 2022, 11, 1030.	4.1	7
35	Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people. Journal of Neuroinflammation, 2022, 19, .	7.2	6
36	P2-305: Omega 3 fatty acids for the prevention of vascular cognitive aging: Methods and rationale for a phase II trial., 2015, 11, P610-P610.		5

3

#	Article	IF	CITATIONS
37	P2-147: A Neuroinflammatory Biomarker Signature of Blood-Brain Barrier Impairment in Older Adults. , 2016, 12, P670-P670.		2
38	Effects of omegaâ€3 fatty acids on cerebral white matter hyperintensities and medial temporal lobe atrophy in older nonâ€demented adults: A 3â€year randomizedâ€controlled phase 2 trial. Alzheimer's and Dementia, 2020, 16, e046608.	0.8	2
39	Pre-Analytical and Within-Person Reproducibility of Nutritional Metabolomics over 2 Years in Elders at Risk for Dementia (P18-121-19). Current Developments in Nutrition, 2019, 3, nzz039.P18-121-19.	0.3	1
40	Blood-based Nutritional Risk Index for Cognition in the Nutrition and Brain Aging Study (NBAS): Emphasis on n-3 PUFA, Vitamin D and Homocysteine (P14-005-19). Current Developments in Nutrition, 2019, 3, nzz052.P14-005-19.	0.3	1
41	P2‶59: Markers of Neuroinflammation Associated with Alzheimer's Disease Pathology in Older Adults. Alzheimer's and Dementia, 2016, 12, P675.	0.8	O
42	[P2–244]: ONEâ€CARBON METABOLISM, COGNITIVE IMPAIRMENT AND CSF MARKERS OF ALZHEIMER PATHOLOGY: HOMOCYSTEINE AND BEYOND. Alzheimer's and Dementia, 2017, 13, P705.	0.8	0
43	F4â€01â€03: A BIOMARKERâ€BASED NUTRITIONAL RISK INDEX EXPLAINS THE HETEROGENEITY IN RATES OF COGNITIVE DECLINE IN THE MULTIâ€DOMAIN ALZHEIMER PREVENTION TRIAL (MAPT). Alzheimer's and Dementia, 2018, 14, P1382.	0.8	0
44	Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging: a proof of principle study. FASEB Journal, 2011, 25, lb277.	0.5	0